Eritromicin (erythromycin) tablets 0.1 №20

Description

Eritromicin Composition
active substance: erythromycin;

1 tablet contains erythromycin – 100 mg;

excipients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate.

Eritromicin Dosage form
Pills.

Basic physical and chemical properties: tablets of a round shape, white or almost white or white with a yellowish tinge, beveled. Subtle inclusions are allowed.

Pharmacotherapeutic group
Antibacterial agents for systemic use. Macrolides. Erythromycin. ATX code J01F A01.

Pharmacodynamics
Erythromycin is a macrolide antibiotic with bacteriostatic action. In high concentrations and in relation to highly sensitive microorganisms, it can have a bactericidal effect. Penetrates through the cell membrane of bacteria and reversibly binds to the 50S subunit of bacterial ribosomes; inhibits the translocation of peptides from the acceptor region of the ribosome to the donor one, preventing further protein synthesis.

Active against gram-positive bacteria: Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae, Staphylococcus aureus, Corynebacterium diphtheriae, Corynebacterium minutissimum, Listeria monocytogenes; gram-negative bacteria: Bordetella pertussis, Legionella pneumophila, some strains of Haemophilus influenzae, Mycoplasma pneumoniae, as well as in relation to Entaemoeba hystolitica, Chlamydia trachomatis, Treponema pallidum.

Gram-negative bacilli are resistant to erythromycin: intestinal, Pseudomonas aeruginosa, as well as Shigella, Salmonella.

Pharmacokinetics
It is absorbed in the digestive tract, while the rate of absorption depends on the individual characteristics of the organism. Bioavailability is 30-65%. The maximum concentration in the blood is reached 2 hours after ingestion. It is distributed in most tissues and body fluids, penetrates the placental barrier and into breast milk.

Plasma protein binding is 70-90%. It is metabolized in the liver, partly with the formation of inactive metabolites. A significant part of erythromycin is excreted in the bile and only 2-5% is excreted unchanged in the urine. The half-life is 1.4-2 hours with normal renal function.

Eritromicin Indications
Respiratory tract infections, including SARS, ENT infections (tonsillitis, otitis media, sinusitis), purulent-inflammatory diseases of the skin and its appendages, erythrasma, diphtheria, gonorrhea, syphilis, listeriosis, Legionnaires’ disease, infections in dentistry and ophthalmology, infections caused by microorganisms resistant to beta-lactam antibiotics, penicillin, tetracycline, chloramphenicol, streptomycin.

Contraindications
Hypersensitivity to erythromycin or to any component of the drug, to macrolides;
Severe liver failure;
The patient has a history of lengthening the QT interval (congenital or acquired, documented) or ventricular arrhythmias, including “torsade de pointes”;
Electrolyte imbalance (hypokalemia, hypomagnesemia – due to the risk of lengthening the QT interval);
Simultaneous use with simvastatin, domperidone, tolterodine, mizolastine, amisulpride, terfenadine, astemizole, pimozide or cisapride, ergotamine and dihydroergotamine.